US drugmaker Pfizer has brought its Rimegepant (Orally Disintegrating Tablet -ODT) to India, to treat acute migraine, in adults with a previous insufficient response to triptan. “The new medication ...

Global pharmaceutical company Pfizer has announced the launch of a Rimegepant Orally Disintegrating Tablet (ODT) in India for acute treatment of migraine in adults with a previous insufficient ...

Migraine is a growing public health concern in India. According to a study published in The Journal of Headache and Pain, nearly 26.3% of people in Delhi NCR suffer from the condition. Pfizer on ...

Drug maker Pfizer on Monday said it has launched a new medication for migraine treatment. The company has introduced Rimegepant ODT in India for adults with a previous insufficient response to triptan ...

Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine. Objective: Migraine is a debilitating chronic disorder requiring multifaceted ...

https://www.thehindubusinessline.com/companies/pfizer-launches-new-medication-for-migraine-treatment/article70290052.ece Copy Drug maker Pfizer on Monday said it has ...

Pfizer launches new migraine drug in India (Image Source: Freepik) Drug maker Pfizer on Monday introduced a new migraine treatment in India, offering hope to millions who struggle with severe and ...

Thomas J. Brock is a CFA and CPA with more than 20 years of experience in various areas including investing, insurance portfolio management, finance and accounting, personal investment and financial ...

AbbVie has submitted its oral CGRP inhibitor atogepant for prevention of both episodic and chronic migraine in the EU as it tries to catch up with main rivals Pfizer/BioHaven and their ...

India, Nov. 17 -- * Rimegepant is an orally disintegrating tablet (ODT) - a class of medications called calcitonin gene-related peptide (CGRP) receptor antagonist * Approved by DCGI for acute ...

Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this year as an acute treatment. The ...